VCNX
Vaccinex, Inc. [VCNX] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
VCNX Stock Summary
Top 10 Correlated ETFs
VCNX
Top 10 Correlated Stocks
VCNX
In the News
VCNX Financial details
Company Rating
Sell
Market Cap
8.69M
Income
-20.23M
Revenue
570K
Book val./share
-2.59
Cash/share
1.72
Dividend
-
Dividend %
-
Employees
37
Optionable
No
Shortable
Yes
Earnings
13 May 2024
P/E
-0.14
Forward P/E
-
PEG
0.04
P/S
13.38
P/B
-0.77
P/C
2.9
P/FCF
-0.45
Quick Ratio
0.17
Current Ratio
0.35
Debt / Equity
-0.11
LT Debt / Equity
-0.01
-
-
EPS (TTM)
-64.31
EPS next Y
-
EPS next Q
-
EPS this Y
-55.24%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-39.11%
Revenue last 5Y
1.74%
Revenue Q/Q
-
EPS Q/Q
-75.62%
-
-
-
-
SMA20
-37.5%
SMA50
-44.44%
SMA100
-58.33%
Inst Own
5.66%
Inst Trans
1.06%
ROA
-857%
ROE
-2657%
ROC
6.05%
Gross Margin
100%
Oper. Margin
-3712%
Profit Margin
-3537%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
5.87-100.8
52W High
-95.01%
52W Low
-0.2%
RSI
24
Rel Volume
0.56
Avg Volume
12.56K
Volume
7.07K
Perf Week
-26.62%
Perf Month
-42.31%
Perf Quarter
-62.84%
Perf Half Y
-60.55%
-
-
-
-
Beta
0.701
-
-
Volatility
0.44%, 1.24%
Prev Close
3.96%
Price
4.99
Change
0%
VCNX Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 8.53 | 0.56 | 6.55 | 0.49 | 1.23 | |
| Net income per share | -521.96 | -327.62 | -169.11 | -97.59 | -43.68 | |
| Operating cash flow per share | -500.77 | -320.22 | -184.15 | -94.39 | -37.17 | |
| Free cash flow per share | -502.04 | -323.46 | -184.38 | -94.88 | -37.31 | |
| Cash per share | 45.26 | 118.44 | 62.52 | 31.63 | 3.31 | |
| Book value per share | -427.76 | -297.06 | 53.95 | 25.7 | -4.98 | |
| Tangible book value per share | -37.07 | -29.2 | 53.95 | 25.7 | -4.98 | |
| Share holders equity per share | -427.76 | -297.06 | 53.95 | 25.7 | -4.98 | |
| Interest debt per share | 0 | 108.39 | 8.73 | 2.41 | 0.53 | |
| Market cap | 62.47M | 38.89M | 30M | 27.35M | 4.32M | |
| Enterprise value | 59.69M | 37.5M | 21.8M | 21.45M | 3.03M | |
| P/E ratio | -1.95 | -1.33 | -1.29 | -1.39 | -0.21 | |
| Price to sales ratio | 119.45 | 777.77 | 33.34 | 273.52 | 7.57 | |
| POCF ratio | -2.03 | -1.36 | -1.19 | -1.43 | -0.25 | |
| PFCF ratio | -2.03 | -1.34 | -1.18 | -1.43 | -0.25 | |
| P/B Ratio | -2.38 | -1.46 | 4.05 | 5.27 | -1.87 | |
| PTB ratio | -2.38 | -1.46 | 4.05 | 5.27 | -1.87 | |
| EV to sales | 114.14 | 750.01 | 24.23 | 214.46 | 5.31 | |
| Enterprise value over EBITDA | -1.89 | -1.34 | -0.98 | -1.09 | -0.13 | |
| EV to operating cash flow | -1.94 | -1.31 | -0.86 | -1.12 | -0.18 | |
| EV to free cash flow | -1.94 | -1.3 | -0.86 | -1.12 | -0.18 | |
| Earnings yield | -0.51 | -0.75 | -0.77 | -0.72 | -4.69 | |
| Free cash flow yield | -0.49 | -0.74 | -0.84 | -0.7 | -4.01 | |
| Debt to equity | 0 | -0.35 | 0.05 | 0.09 | -0.11 | |
| Debt to assets | 0 | 0.79 | 0.04 | 0.06 | 0.07 | |
| Net debt to EBITDA | 0.09 | 0.05 | 0.37 | 0.3 | 0.06 | |
| Current ratio | 0.58 | 0.86 | 4.17 | 2.95 | 0.57 | |
| Interest coverage | 0 | -57.94 | -27.8 | -9.95K | -22.89K | |
| Income quality | 0.96 | 0.99 | 1.13 | 0.96 | 0.85 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 12.75 | 148.1 | 6.92 | 62.02 | 12.07 | |
| Research and developement to revenue | 49.08 | 430.98 | 19.07 | 139.79 | 28.87 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0.01 | 0 | 0.01 | 0 | |
| Capex to revenue | -0.15 | -5.8 | -0.04 | -0.99 | -0.12 | |
| Capex to depreciation | -0.31 | -0.94 | -0.19 | -0.48 | -0.56 | |
| Stock based compensation to revenue | 0.85 | 14.64 | 0.6 | 5.45 | 0.83 | |
| Graham number | 2.24K | 1.48K | 453.09 | 237.55 | 69.99 | |
| ROIC | 1.23 | 1.66 | -2.94 | -3.31 | 11.93 | |
| Return on tangible assets | -6.95 | -2.5 | -2.36 | -2.47 | -5.58 | |
| Graham Net | -55.9 | -40.24 | 44.83 | 18.5 | -7.95 | |
| Working capital | -2.87M | -1.89M | 7.15M | 4.94M | -2.57M | |
| Tangible asset value | -2.27M | -2.61M | 7.41M | 5.19M | -2.31M | |
| Net current asset value | -2.87M | -3.03M | 6.97M | 4.69M | -2.59M | |
| Invested capital | 0 | -0.35 | 0.05 | 0.09 | -0.11 | |
| Average receivables | 768.5K | 527.5K | 78.5K | 87.5K | 568K | |
| Average payables | 2.77M | 3.19M | 2.12M | 1.29M | 1.78M | |
| Average inventory | 0.5 | 1 | 0.5 | 0.5 | 0.5 | |
| Days sales outstanding | 626.71 | 1.15K | 0 | 638.75 | 615.38 | |
| Days payables outstanding | 5.88K | 578.34K | 2.29K | 2.68K | 6.25K | |
| Days of inventory on hand | 0 | 0.18 | 0 | 0 | 0 | |
| Receivables turnover | 0.58 | 0.32 | 0 | 0.57 | 0.59 | |
| Payables turnover | 0.06 | 0 | 0.16 | 0.14 | 0.06 | |
| Inventory turnover | 199K | 2K | 0 | 207K | 0 | |
| ROE | 1.22 | 1.1 | -3.13 | -3.8 | 8.76 | |
| Capex per share | -1.27 | -3.24 | -0.23 | -0.49 | -0.14 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.23 | 2.32 | 0 | 0.06 | 0 | |
| Net income per share | -22.96 | -20.79 | -24.54 | -15.26 | -3.72 | |
| Operating cash flow per share | -21.04 | -21.22 | -19.14 | -9.61 | -4.02 | |
| Free cash flow per share | -21.27 | -21.42 | -19.14 | -9.67 | -4.02 | |
| Cash per share | 29.24 | 13.99 | 6.63 | 0.39 | 1.72 | |
| Book value per share | 23.76 | 10.1 | -1.47 | -12.02 | -2.59 | |
| Tangible book value per share | 23.76 | 10.1 | -1.47 | -12.02 | -2.59 | |
| Share holders equity per share | 23.76 | 10.1 | -1.47 | -12.02 | -2.59 | |
| Interest debt per share | 2.22 | 1.7 | 1.28 | 0.95 | 0.71 | |
| Market cap | 29.58M | 19.93M | 21.51M | 5.09M | 8.31M | |
| Enterprise value | 23.68M | 17.03M | 19.97M | 5.27M | 7.02M | |
| P/E ratio | -1.47 | -1.01 | -0.76 | -0.26 | -0.63 | |
| Price to sales ratio | 591.67 | 36.23 | 0 | 254.64 | 0 | |
| POCF ratio | -6.43 | -3.95 | -3.91 | -1.65 | -2.31 | |
| PFCF ratio | -6.36 | -3.92 | -3.91 | -1.64 | -2.31 | |
| P/B Ratio | 5.7 | 8.3 | -50.85 | -1.32 | -3.6 | |
| PTB ratio | 5.7 | 8.3 | -50.85 | -1.32 | -3.6 | |
| EV to sales | 473.55 | 30.97 | 0 | 263.64 | 0 | |
| Enterprise value over EBITDA | -4.7 | -3.45 | -2.84 | -0.9 | -1.42 | |
| EV to operating cash flow | -5.15 | -3.38 | -3.63 | -1.7 | -1.95 | |
| EV to free cash flow | -5.09 | -3.35 | -3.63 | -1.69 | -1.95 | |
| Earnings yield | -0.17 | -0.25 | -0.33 | -0.96 | -0.4 | |
| Free cash flow yield | -0.16 | -0.26 | -0.26 | -0.61 | -0.43 | |
| Debt to equity | 0.09 | 0.18 | -0.87 | -0.08 | -0.11 | |
| Debt to assets | 0.06 | 0.09 | 0.12 | 0.12 | 0.07 | |
| Net debt to EBITDA | 1.17 | 0.59 | 0.22 | -0.03 | 0.26 | |
| Current ratio | 2.95 | 1.91 | 0.79 | 0.35 | 0.57 | |
| Interest coverage | -5.12K | 207.75 | 0 | 0 | -13.02 | |
| Income quality | 0.91 | 1.02 | 0.78 | 0.63 | 1.08 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 32.06 | 3.13 | 0 | 74.95 | 0 | |
| Research and developement to revenue | 74.82 | 6.93 | 0 | 217.75 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.01 | 0.01 | 0 | 0.01 | 0 | |
| Capex to revenue | -1 | -0.09 | 0 | -0.9 | 0 | |
| Capex to depreciation | -1.11 | -1.58 | 0 | -0.58 | 0 | |
| Stock based compensation to revenue | 2.64 | 0.23 | 0 | 5.75 | 0 | |
| Graham number | 110.8 | 68.75 | 28.49 | 64.24 | 14.71 | |
| ROIC | -0.84 | -1.6 | -41.01 | 1.72 | 2.6 | |
| Return on tangible assets | -0.63 | -1.01 | -2.29 | -1.92 | -0.91 | |
| Graham Net | 17.1 | 3.49 | -5.53 | -17.4 | -4.13 | |
| Working capital | 4.94M | 2.11M | -704K | -4.16M | -2.57M | |
| Tangible asset value | 5.19M | 2.4M | -423K | -3.87M | -2.31M | |
| Net current asset value | 4.69M | 1.92M | -829K | -4.22M | -2.59M | |
| Invested capital | 0.09 | 0.18 | -0.87 | -0.08 | -0.11 | |
| Average receivables | 112.5K | 87.5K | 5.5K | 472K | 947K | |
| Average payables | 1.01M | 1.31M | 1.35M | 2.92M | 3.13M | |
| Average inventory | 0.5 | 0.5 | 0.5 | 0.5 | 0 | |
| Days sales outstanding | 315 | 0 | 0 | 4.2K | 0 | |
| Days payables outstanding | 3.04K | 3.17K | 4.82K | 12.27K | 6.92K | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0.29 | 0 | 0 | 0.02 | 0 | |
| Payables turnover | 0.03 | 0.03 | 0.02 | 0.01 | 0.01 | |
| Inventory turnover | 45K | 0 | 30K | 0 | 0 | |
| ROE | -0.97 | -2.06 | 16.69 | 1.27 | 1.44 | |
| Capex per share | -0.23 | -0.21 | 0 | -0.06 | 0 |
VCNX Frequently Asked Questions
What is Vaccinex, Inc. stock symbol ?
Vaccinex, Inc. is a US stock , located in Rochester of Ny and trading under the symbol VCNX
What is Vaccinex, Inc. stock quote today ?
Vaccinex, Inc. stock price is $4.99 today.
Is Vaccinex, Inc. stock public?
Yes, Vaccinex, Inc. is a publicly traded company.
Company Profile
- Volume Average 12.56K
- Market Capitalization 8.69M
- Employee 37
- CEO Dr. Maurice Zauderer Ph.D.
- Headquarters Rochester,NY,US
- IPO Date 2018-08-09
-
Website
https://www.vaccinex.com 
Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs. The company offers its products for the treatment of cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab, a humanized monoclonal antibody that completed and planned Phase 1b/2 clinical trials for the treatment of non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), Huntington's disease, Alzheimer's disease, osteosarcoma, and melanoma. The company is also developing VX5, a human antibody to CXCL13 that is in preclinical development for the treatment of MS and for other autoimmune disorders. Vaccinex, Inc. was incorporated in 2001 and is headquartered in Rochester, New York.
